摘要
目的探讨艾迪注射液对中晚期结肠癌患者的临床疗效及免疫功能的影响。方法选取2012年1月至2019年1月云南省肿瘤医院收治的130例中晚期结肠癌患者,根据随机数字表法分为对照组和观察组,各65例。对照组采用mFOLFOX6化疗方案,观察组在对照组基础上联合艾迪注射液静脉注射,14 d为1个周期,2组均治疗4个周期。比较2组的临床疗效及治疗前(T_(0))、完成2个周期化疗(T_(1))、完成4个周期化疗(T_(2))时血清免疫功能指标、外周血血常规指标水平。随访12个月,记录随访期间无进展生存期(PFS)及总生存期。结果观察总有效率高于对照组[93.8%(61/65)比76.9%(50/65)],差异有统计学意义(P<0.05)。2组T_(1)时点血清前白蛋白、白蛋白、免疫球蛋白(Ig)G、IgA、IgM水平均低于T0时点(均P<0.05),但组间比较差异均无统计学意义(均P>0.05);2组T_(2)时点血清前白蛋白、白蛋白、IgG、IgA、IgM水平均高于T_(1)时点,且观察组均高于对照组[(0.29±0.08)g/L比(0.22±0.06)g/L、(37±7)g/L比(33±6)g/L、(11.9±1.3)g/L比(9.4±1.2)g/L、(2.7±0.7)g/L比(2.4±0.6)g/L、(1.8±0.5)g/L比(1.6±0.4)g/L](均P<0.05)。2组T1时点白细胞计数(WBC)、红细胞计数(RBC)、血小板计数(PLT)及血红蛋白水平均低于T_(0)时点(均P<0.05),但组间比较差异均无统计学意义(均P>0.05);2组T_(2)时点WBC、PLT及血红蛋白水平均高于T_(1)时点,且观察组均高于对照组,观察组T_(2)时点RBC水平高于T_(1)时点,且高于对照组,差异均有统计学意义(均P<0.05)。观察组化疗期间恶心呕吐、腹泻及便秘比例均低于对照组,差异均有统计学意义(均P<0.05)。随访期间观察组PFS、总生存期均长于对照组,差异均有统计学意义(均P<0.001)。结论艾迪注射液可提高中晚期结肠癌患者免疫功能及白蛋白和白细胞水平,减少化疗毒性作用,改善患者预后。
Objective To investigate the clinical effect of Aidi injection on patients with middle-advanced colon cancer and its influence on immune function.Methods From January 2012 to January 2019,130 patients with middle-advanced colon cancer admitted to Yunnan Cancer Hospital were enrolled.They were randomly divided into control group and observation group,with 65 cases in each group.The control group was treated with mFOLFOX6 chemotherapy regimen,and the observation group was treated with Aidi injection on the basis of the control group.Both groups were treated for 4 cycles(14 d for 1 cycle).Curative effect,serum immune function indexes,peripheral blood routine indexes levels at the time points of before treatment(T_(0)),completion of 2 cycles of chemotherapy(T_(1))and completion of 4 cycles of chemotherapy(T_(2))were compared.Progression free survival(PFS)and overall survival were recorded during follow-up for 12 months.Results The effective rate of the observation group was higher than that of the control group[93.8%(61/65)vs 76.9%(50/65)],and the difference was statistically significant(P<0.05).At T_(1)time point,the serum levels of prealbumin,albumin,immunoglobulin(Ig)G,IgA and IgM in both groups were lower than those at T_(0)time point(all P<0.05),but there were no significant differences between the two groups(all P>0.05);at T_(2)time point,the serum levels of prealbumin,albumin,IgG,IgA and IgM in both groups were higher than those at T_(1)time point,and those in observation group were higher than those in control group[(0.29±0.08)g/L vs(0.22±0.06)g/L,(37±7)g/L vs(33±6)g/L,(11.9±1.3)g/L vs(9.4±1.2)g/L,(2.7±0.7)g/L vs(2.4±0.6)g/L,(1.8±0.5)g/L vs(1.6±0.4)g/L](all P<0.05).At T_(1)time point,the white blood cell count(WBC),red blood cell count(RBC),platelet count(PLT)and hemoglobin levels in both groups were lower than those at T_(0)time point(all P<0.05),but there were no significant differences between the two groups(all P>0.05);at T_(2)time point,WBC,PLT and hemoglobin levels in both groups were higher than those at T_(1)time point,RBC level in observation group was higher than that at T_(1)time point,and those in observation group were higher than those in control group(all P<0.05).The proportions of nausea and vomiting,diarrhea,and constipation in observation group were lower than those in control group(all P<0.05).During the follow-up period,the PFS and overall survival in observation group were longer than those in control group(both P<0.001).Conclusion Aidi injection can increase immune function,albumin and white blood cells levels in patients with middle-advanced colon cancer,reduce toxicity caused by chemotherapy,and improve prognosis.
作者
张麒
马晓骉
李勇
叶秋文
潘定国
Zhang Qi;Ma Xiaobiao;Li Yong;Ye Qiuwen;Pan Dingguo(Department of Hepatopancreatobiliary Surgery,Yunnan Cancer Hospital,Kunming 650118,China;Biotherapeutic Center,Yunnan.Cancer Hospital,Kunming 650118,China;Department of Colorectal Cancer,Yunnan Cancer Hospital,Kunming 650118 China)
出处
《中国医药》
2021年第4期583-587,共5页
China Medicine
基金
云南省科技计划(202001AY070001-236)。
关键词
结肠癌
艾迪注射液
免疫功能
Colon cancer
Aidi injection
Immune function
